Selank: The Complete Guide
A seven-amino-acid peptide developed at the same Russian institute as Semax. Where Semax targets BDNF for cognitive research, Selank targets GABA pathways for anxiolytic research. Approved as a prescription medication in Russia for generalised anxiety disorder.
What is Selank?
Here is the simplest way to understand Selank: it is the calming sister peptide of Semax. Both were developed at the same Russian institute (the Institute of Molecular Genetics, Russian Academy of Sciences) — by the same team, using the same design strategy. Both are seven amino acids long. Both end in the same three-amino-acid stabilising tail (Pro-Gly-Pro). But they are built from different parent molecules and target different systems. Semax comes from a fragment of the stress hormone ACTH. Selank comes from a fragment of an immune-system peptide called tuftsin.
Tuftsin (Thr-Lys-Pro-Arg) is a naturally occurring four-amino-acid peptide your body produces from a fragment of the immunoglobulin G heavy chain — a piece of your own antibodies. Tuftsin was originally studied for its immune-system effects, but researchers discovered it also had effects on the central nervous system. The problem was that tuftsin degraded too quickly in the body to be useful. The Russian team added the same Pro-Gly-Pro tail they had used for Semax, and the result was Selank — a stabilised version with much longer activity.
What sets Selank apart in the cognitive research family is its dual profile. Research suggests Selank produces anxiolytic effects (research-described as comparable to benzodiazepines in published Russian clinical trials) combined with nootropic activity — meaning anxiety-calming research findings without the sedation, memory impairment, or dependence concerns historically associated with benzodiazepines. Selank is registered as a pharmaceutical in Russia and is prescribed for generalised anxiety disorder and neurasthenia. As with Semax, this gives Selank a substantial real-world clinical evidence base in Russia. It is not approved by the FDA, EMA, or TGA, and the bulk of the published research originates from Russian institutions. The honest institutional framing is that the evidence base is substantial but geographically concentrated.
Research Applications
Research on Selank spans the GABAergic mechanism that drives the anxiolytic activity, the broader monoamine modulation that produces the unusual nootropic-plus-calming dual profile, and the BDNF and immune-system effects inherited from the tuftsin parent molecule.
Russian clinical trials examined Selank against medazepam (a benzodiazepine reference compound) and research suggests comparable anxiolytic effects — without sedation, amnesia, or dependence concerns. Research suggests Selank can produce anxiolytic activity through a fundamentally different mechanism than benzodiazepines, even though both end up modulating GABAergic neurotransmission.
Where benzodiazepines tend to dampen cognitive performance, research suggests Selank does the opposite — producing nootropic effects alongside its anxiolytic activity. Research suggests this comes from monoamine modulation (serotonin, dopamine, noradrenaline) layered on top of the GABAergic effect.
Research suggests Selank also rapidly increases BDNF expression in the hippocampus — the same growth factor that Semax upregulates. The two peptides share this neurotrophic effect, even though each has a different primary target system. The Pro-Gly-Pro tail itself appears to contribute to the BDNF response in both compounds.
Tuftsin is a natural immune peptide derived from your own antibodies (the IgG heavy chain). Research suggests Selank retains some of these immunomodulatory and antiviral properties from the parent molecule — an unusual additional research lane alongside the central nervous system work.
One of the central institutional positioning points: research suggests Selank does not produce the tolerance, physical dependence, or withdrawal patterns historically associated with benzodiazepine therapy — even after extended administration. This is the key differentiation from the benzodiazepine class in published Russian research.
Selank is registered as a pharmaceutical medication in Russia — prescribed for generalised anxiety disorder (GAD) and neurasthenia. Available in Russian pharmacies. Not approved by the FDA, EMA, or TGA. The Russian clinical evidence base is substantial; the geographic concentration of the research literature is honest institutional context.
How Selank Works
The big-picture answer first: Selank works through several overlapping mechanisms, but the central anxiolytic story involves GABA — the brain's main inhibitory neurotransmitter, the molecule that calms neuronal activity. Research suggests Selank enhances GABAergic signalling through an allosteric mechanism that is distinct from how benzodiazepines work, while also modulating serotonin, dopamine, and noradrenaline systems and activating BDNF expression like its sister peptide Semax.
GABA in plain language: GABA (gamma-aminobutyric acid) is the brain's primary brake. Where neurotransmitters like glutamate excite neurons and turn them up, GABA does the opposite — it slows neurons down, calms activity, and produces the feeling of being settled rather than activated. The GABAA receptor is the main receptor that GABA acts through. Benzodiazepines work by binding to a specific site on the GABAA receptor (the benzodiazepine site) that amplifies how strongly GABA can activate the receptor. Research suggests Selank produces a similar net effect — enhanced GABAergic activity — but through a different mechanism.
The mechanism difference: research suggests Selank acts as an allosteric modulator of the GABAA receptor, but instead of binding the benzodiazepine site, it appears to change the number of GABA binding sites available — a different way of enhancing GABAergic activity. This mechanistic distinction is the proposed pharmacological basis for why research suggests Selank does not produce the tolerance, dependence, or withdrawal patterns associated with benzodiazepines. Same downstream effect (increased GABAergic transmission), different upstream mechanism, different long-term profile.
Monoamine modulation: alongside the GABAergic effect, research suggests Selank modulates the activity and metabolism of serotonin, dopamine, and noradrenaline — the three main monoamine neurotransmitters involved in mood, motivation, attention, and arousal. Research suggests this triple modulation is the proposed basis for the nootropic activity that runs alongside the anxiolytic activity. Picture the GABAergic mechanism as the calming layer, and the monoamine modulation as the cognitive-clarity layer.
Enkephalinase inhibition: both Selank and Semax inhibit enzymes called enkephalinases — the enzymes responsible for breaking down enkephalins and other endogenous regulatory peptides. Research suggests by extending the activity of these natural regulatory peptides, Selank may contribute to emotional regulation and stress resilience through pathways the body already uses internally, rather than introducing exogenous opioid signalling.
BDNF effects shared with Semax: research suggests Selank also rapidly increases BDNF expression in the hippocampus, similar to its sister peptide Semax. The Pro-Gly-Pro tail that both peptides share appears to contribute independently to the BDNF response. This is part of why research suggests the two peptides produce broader neurotrophic effects than their primary mechanisms (GABAergic for Selank, BDNF-direct for Semax) would predict.
Storage Guidelines
Store at 2–8°C in a cool, dry place. Protect from light and moisture. Refrigerate once in solution form.
Frequently Asked Questions
Technical Specifications
Compiled by the Southern Pacific Labs research team. Last updated April 2026.
Published References
- Zozulia AA, Neznamov GG, Siuniakov TS, et al. “[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia].” Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2008. PubMedThe foundational Russian clinical trial paper — the study that examined Selank against medazepam (a benzodiazepine reference) in generalised anxiety disorder and supported the Russian pharmaceutical approval. Important reading for understanding the clinical evidence base behind the central institutional positioning.
- Volkova A, Shadrina M, Kolomin T, et al. “Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission.” Frontiers in pharmacology, 2016. PubMedA mechanistic study examining how Selank affects the expression of genes involved in GABAergic neurotransmission. Important for understanding the molecular basis of the GABA-pathway mechanism that distinguishes Selank from benzodiazepines.
- Kasian A, Kolomin T, Andreeva L, et al. “Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats.” Behavioural neurology, 2017. PubMedAn animal study examining whether Selank can enhance the anxiolytic effect of diazepam in chronic stress models. Useful for understanding how Selank interacts with the broader GABAergic pharmacology landscape rather than working in isolation.
- Filatova E, Kasian A, Kolomin T, et al. “GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells.” Frontiers in pharmacology, 2017. PubMedA cell-culture study comparing Selank's effects on GABAergic gene expression against natural GABA itself and an antipsychotic reference compound. Useful comparative pharmacology for understanding what Selank shares with and what it differs from in the broader neuropsychiatric research family.
Browse all Selank research on PubMed →
Related Research Guides
More in Bioregulators & Neuropeptides
Sister peptide from the same Russian research institute — same Pro-Gly-Pro stabilising tail, but built from ACTH instead of tuftsin. Targets BDNF and cognitive research where Selank targets GABA and anxiolytic research. Designed to be complementary.
Read guide →TREK-1 Channel InhibitorA different angle on cognitive and mood research from Selank's GABAergic mechanism — works by blocking the TREK-1 potassium channel, which research suggests removes a brake on neuronal activity and supports neurogenesis.
Read guide →Evidence and publication statusAn angiotensin IV-derived compound whose evidence includes a retracted mechanism paper and an earlier expression of concern. Read the updated evidence limitations.
Read guide →